Eli Lilly and Company Stock price

Equities

LLY

US5324571083

Pharmaceuticals

Market Closed - Nyse 04:00:02 2024-03-18 pm EDT 5-day change 1st Jan Change
762.7 USD +1.13% Intraday chart for Eli Lilly and Company +3.85% +30.83%
Sales 2024 * 41.35B Sales 2025 * 51.31B Capitalization 687B
Net income 2024 * 10.93B Net income 2025 * 15.81B EV / Sales 2024 * 16.9 x
Net Debt 2024 * 13.51B Net Debt 2025 * 7.93B EV / Sales 2025 * 13.5 x
P/E ratio 2024 *
62.9 x
P/E ratio 2025 *
42.7 x
Employees 43,000
Yield 2024 *
0.68%
Yield 2025 *
0.77%
Free-Float 99.71%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.29%
1 week+3.85%
Current month+1.19%
1 month-2.48%
3 months+31.55%
6 months+33.50%
Current year+30.83%
More quotes
1 week
745.71
Extreme 745.71
769.68
1 month
727.62
Extreme 727.62
800.78
Current year
579.05
Extreme 579.05
800.78
1 year
323.26
Extreme 323.26
800.78
3 years
178.58
Extreme 178.5779
800.78
5 years
101.36
Extreme 101.36
800.78
10 years
56.81
Extreme 56.81
800.78
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 95-12-31
Director of Finance/CFO 51 13-09-30
President - -
Members of the board TitleAgeSince
Director/Board Member 64 21-01-24
Director/Board Member 67 09-03-31
Director/Board Member 64 04-12-31
More insiders
Date Price Change Volume
24-03-18 762.7 +1.13% 2,521,351
24-03-15 754.2 -0.86% 3,730,053
24-03-14 760.7 +0.38% 2,647,549
24-03-13 757.8 +0.38% 2,357,486
24-03-12 755 +2.80% 2,701,718

Delayed Quote Nyse, March 18, 2024 at 04:00 pm EDT

More quotes
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (46.6%): products for treating osteoporosis, diabetes, and growth problems; - oncology (20.3%); - immunology diseases (11.8%); - neurology (6.7%): primarily drugs used in treating depression and schizophrenia; - other (14.6%). Net sales are distributed geographically as follows: the United States (59.4%), Europe (16.9%), Japan (8.3%), China (5.9%) and other (9.5%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
762.7 USD
Average target price
790.5 USD
Spread / Average Target
+3.65%
Consensus
  1. Stock
  2. Equities
  3. Stock Eli Lilly and Company - Nyse